Skip to Main Content

Paper Details

Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder.
J Neurol Neurosurg Psychiatry
7
2023
C, IgG, IgG), N, N-MOmentum, NMOSD, aquaporin-4, glial, immunoglobulin G (, inebilizumab, myelin, myelin oligodendrocyte glycoprotein-, neurofilament light chain, neuromyelitis optica spectrum disorder, participants, patients, relapsing-remitting multiple sclerosis, sGFAP, sNfL, sTau, sUCHL1, serum neurofilament light chain, tau, ubiquitin C-terminal hydrolase L1
Author NameAffiliation
Hans-Peter HartungHeinrich Heine University Dusseldorf
Hans-Peter HartungPalacky University in Olomouc
Hans-Peter HartungMedical University Vienna
Hans-Peter HartungUniversity of Sydney
Friedemann PaulExperimental and Clinical Research Center, Max Delbruck Center for Molecular Medicine and Charite, Universitatsmedizin Berlin
Gary CutterUniversity of Alabama at Birmingham
Bruce A C CreeWeill Institute for Neurosciences, University California of San Francisco
  • 1 - 7

Datasets

Release 1.2